

Investor Fact Sheet


MISONIX, INC.

February 2008
Nasdaq: MSON



PROFILE

Nasdaq Symbol	MSON
Market Cap.	\$30M
Price (2/15)	\$4.34
52-Week Range	\$3.82-\$7.49
Outstanding Shares	7.00M
Daily Volume	7,300
Net Sales (LQA)	\$46M
Total Assets	\$36M



HIGHLIGHTS

- Premier Platform of Ultrasonic Medical Devices
- Focus on Cancer Ablation Using Emerging HIFU (Ultrasound) Technology
- Impressive Distribution Network & High Barriers to Entry
- Robust Product Pipeline; Diversification Through Product Mix and Region
- Healthy Balance Sheet

HIFU & THERAPEUTIC ULTRASONIC MEDICAL DEVICES AND EQUIPMENT

Misonix, Inc. has been at the forefront of ultrasonic technology for over 50 years. The Company is a world leader in the design, development and manufacturing of ultrasonic medical devices. Devices are both internally developed and based on licensed technology, and focus on ablation of cancer and benign tumors as well as other therapeutic applications. In addition, Misonix designs, develops, manufactures, and markets scientific and industrial ultrasonic equipment, laboratory safety equipment and air pollution control products.

Misonix's ultrasonic platform is the basis for several innovative medical technologies. Included is High Intensity Focused Ultrasound (HIFU), which is a state-of-the-art technology utilizing the power of ultrasound to destroy abnormal tissue while minimally affecting surrounding healthy tissue. *Fortified by proprietary research and the benefits of HIFU, Misonix is positioned as the only US public company with a primary focus on the ultrasonic treatment of cancer.*

A strategic advantage for Misonix is a diversified platform of commercialized

products and services. Far beyond a development stage company, Misonix has demonstrated impressive revenues for existing medical devices and has completed the development of significant new products for introduction in 2008.



Misonix has been investing for future exponential growth. In particular, management has increased funding of R&D, expanded its sales and marketing efforts, and is upgrading to a digital ultrasonic platform.

Track Record of Execution

	FY 1999	FY 2007
Revenue	\$25 Million	\$42 Million
Medical Devices	1	13
R&D as % of Sales	4%	7%

Focus on Key Growth Initiatives

- ✓ Grow European Distribution
- ✓ Support Launch of SonicOne® for Wound Care
- ✓ Distribution and Launch of Bone Cutter
- ✓ Sales of Sonatherm for Kidney Cancer
- ✓ Grow Distribution in Latin America
- ✓ New Products and Line Extensions



Investor Fact Sheet

February 2008



<i>Ultrasonic Platform (Partial List)</i>	<i>Strategic Partners</i>	<i>Market Size (Annual)</i>	<i>Stage</i>
Prostate cancer and benign tumor treatment	Licensed HIFU from Focus Surgery; direct distribution in Europe	\$750 million estimated	Commercial in Europe and Asia; FDA trials in US
Liver cancer and benign tumor treatment	Misonix has HIFU rights for development and global commercialization	\$700 million Estimated	Development
Breast cancer and benign tumor treatment	Misonix has HIFU rights for development and global commercialization	\$600 million estimated	Development
Kidney cancer and benign tumor treatment	Misonix has HIFU rights for development and global commercialization	\$150 million estimated	FDA 510(k); clinical studies being conducted in Europe
Wound debridement	Internally developed and distributed directly in U.S.; SIAD Healthcare in Italy; planning on expanding int'l dist.	\$3 billion estimated	Commercial
Laparoscopic and open surgery tissue cutting and coagulation	Proprietary technology licensed to Covidien (NYSE: COV)	\$120 million estimated	Commercial
Neurosurgery and General Surgery	Distributed in the US by Aesculap; proprietary distributors outside of the U.S.	\$80 million estimated	Commercial
Kidney and bladder stone removal	Proprietary technology distributed worldwide through agreement with ACM	\$10 million estimated	Commercial
Cosmetic Surgery/Liposuction	Distributed in the U.S. by Mentor Corp. (NYSE: MNT); proprietary distributors outside of the U.S.	\$40 million estimated	Commercial
Equipment testing/refurbishment	Sonora (93.75% owned by Misonix)	\$500 million	Commercial

COMPANY INFO:

Misonix, Inc.
1938 New Highway
Farmingdale, NY 11735
631-694-9555
www.misonix.com
Nasdaq: MSON

Michael McManus, Jr.
President, CEO
Richard Zaremba
SVP, CFO

IR CONTACT INFO:

Jordan Darrow
Darrow Associates, Inc.
631-367-1866
jdarow@DarrowIR.com

Future Growth Driven By Robust Product Pipeline Focused On Cancer

Finding a cure for cancer before it strikes remains elusive despite significant funding from public and private sectors for advanced research. Chemotherapy, radiation and new drug treatments for patients diagnosed with cancer have met with some success, but the side effects and long term impacts limit the desirability of these methods.

Across a broad spectrum of therapeutic and diagnostic applications, ultrasound devices - particularly those using HIFU - have proven to be minimally invasive, life enhancing, efficient, and patient-friendly. The SB500 has been used successfully in more than 5,000 procedures. Its European distribution, most notably on a fee-per-use basis, is rapidly growing as prominent

doctors recognize the value of this treatment.

Leveraging its continued investment in R&D of ultrasonic technology, Misonix is laying the groundwork for years of profitable revenue growth with a diversified portfolio of medical devices, including those for wound debridement, bone cutting and HIFU treatment of abnormal tissue, including breast, liver and kidney. Based on the strength and prospects for the Company's established businesses, Misonix has significantly increased funding of medical research and development.

Misonix has a healthy balance sheet and working capital position with access to an \$8 million asset based line to fund future growth opportunities as an ultrasound medical devices story with the greatest number of products in the market.

This material is for informational purposes only. Forward-looking statements contained in this Fact Sheet are within the meaning provided by the Private Securities Litigation Reform Act of 1995 and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied herein. Please refer to Misonix's various Securities and Exchange Commission filings for a more detailed discussion of these risks. This Fact Sheet should not be construed as a recommendation to purchase or sell Misonix's common shares.

Copyright 2008 Misonix, Inc. All rights reserved.